Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
prme · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$23.00
Consensus
$17.25
+476.9% upside
Low
$12.00
Median: $17 · Last Close: $2.99
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$17.25
476.9% upside
High Target
$23
669.2%
Low Target
$12
301.3%
Current Price
$2.99
as of today
Based on analyst price targets, the PRME stock price prediction for the next 12 months ranges from $12 to $23. The consensus PRME price forecast of $17.25 implies 476.9% upside from the current price of $2.99.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.02 | ↑ 1.13% |
1-day model range: $2.99–$3.06. Peak: $3.06 (+1.13%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -63.7% |
| 2029 | $1 | -69.2% |
| 2030 | $1 | -71.8% |
| 2031 | — | -73.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PRME · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-11 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-10 | Chardan Capital | Maintains | Buy→Buy |
| 2025-08-12 | Citigroup | Maintains | Neutral→Neutral |
| 2025-08-08 | Chardan Capital | Maintains | Buy→Buy |
| 2025-05-27 | Citigroup | Downgrade ↓ | Buy→Neutral |
| 2025-05-20 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2025-05-20 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-05-20 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-05-19 | Chardan Capital | Maintains | Buy→Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Prime Medicine, Inc. (PRME) stock. Of the recent 25 rating actions, 1 were upgrades and 3 were downgrades. 9 analysts currently cover PRME.
Analyst Recommendation Trends
PRME analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$13M
↓ 58.7% YoY
Revenue Next Year
$23M
↑ 74.1% YoY
EPS This Year
$-1.00
EPS Next Year
$-0.91
↓ 8.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast PRME EPS of $-1.00 for the current fiscal year, based on estimates from 9 analysts. The PRME revenue forecast is $13M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PRME stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PRME price target is $17.25 (+476.9% upside), with an analyst consensus of Buy.
The PRME short-term stock prediction for tomorrow is $3.02 (+1.13%). The PRME stock price prediction for 2027 estimates an average of $2. The PRME stock prediction for 2030 projects a range of $1–$1.
Prime Medicine, Inc. trades on NASDAQ under the ticker PRME. The PRME stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.
Frequently asked questions
PRME forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month PRME price target is $17.25, with a high forecast of $23.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +476.9% potential upside from the current price of $2.99.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.